Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: NTLA) | Delayed: 11.21 +0.05 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.16 | 52 Week High | $30.40 | |||
| Open | $11.00 | 52 Week Low | $11.86 | |||
| Day High | $11.24 | P/E | N/A | |||
| Day Low | $10.58 | EPS | $0.00 | |||
| Volume | 3,564,678 | |||||
